Several prior retrospective studies have not found that steroids reduce antitumor immune activity.43 On the other hand, prior in vitro and animal experiments have shown that glucocorticoids block antibody‐dependent tumor cell destruction44; may abrogate interleukin‐1α‐mediated antitumor activity45; and upregulate CTLA‐4 in animal models of intracranial gliomas responsive to CTLA‐4 inhibition.46 A recent study concluded in addition that infliximab, in contrast to corticosteroids, had little to no negative impact on tumor‐infiltrating lymphocyte function.47 This evidence concerns the gene CTLA4 and neoplasm.